CD19 CAR-T Therapy Triples Remission in Refractory Autoimmune Diseases
Baca dalam 60 detik
- All patients had failed multiple lines of therapy, including biologics and JAK inhibitors, highlighting the therapy's potency.
- Remission persisted at 6-month follow-up with no severe adverse events.
- CD19 CAR-T therapy, originally approved for B-cell malignancies, redirects engineered T cells to eliminate CD19-expressing B cells.
The study reported three patients with severe, treatment-resistant autoimmune diseases achieving complete remission after a single infusion of CD19 CAR-T cells. All patients had failed multiple lines of therapy, including biologics and JAK inhibitors, highlighting the therapy's potency. Remission persisted at 6-month follow-up with no severe adverse events.
CD19 CAR-T therapy, originally approved for B-cell malignancies, redirects engineered T cells to eliminate CD19-expressing B cells. In autoimmune diseases, this depletes pathogenic B cells that produce autoantibodies and present self-antigens. The approach resets the immune system, potentially offering durable remission without continuous immunosuppression.
This triple remission provides proof-of-concept for CAR-T therapy in autoimmune indications, expanding its therapeutic horizon. Regulatory agencies may fast-track approvals given the unmet need in refractory patients. The next step involves larger trials to confirm efficacy and safety across diverse autoimmune populations.
Power Move: CD19 CAR-T therapy is poised to disrupt the autoimmune treatment landscape, challenging the current step-care paradigm. If larger trials validate these results, expect rapid regulatory expansion and a race among biotechs to develop off-the-shelf CAR-T products for autoimmune diseases.
This article was edited with AI assistance for readability. Read original here.
